Literature DB >> 28153383

Non-Hodgkin lymphoma.

James O Armitage1, Randy D Gascoyne2, Matthew A Lunning3, Franco Cavalli4.   

Abstract

Lymphomas can affect any organ in the body, present with a wide range of symptoms, and be seen by primary care physicians and physicians from most specialties. They are traditionally divided into Hodgkin's lymphoma (which accounts for about 10% of all lymphomas) and non-Hodgkin lymphoma, which is the topic of this Seminar. Non-Hodgkin lymphoma represents a wide spectrum of illnesses that vary from the most indolent to the most aggressive malignancies. They arise from lymphocytes that are at various stages of development, and the characteristics of the specific lymphoma subtype reflect those of the cell from which they originated. Since this topic was last reviewed in The Lancet in 2012, advances in understanding the biology and genetics of non-Hodgkin lymphoma and the availability of new diagnostic methods and therapies have improved our ability to manage patients with this disorder.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28153383     DOI: 10.1016/S0140-6736(16)32407-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  122 in total

Review 1.  Breast Implant-Associated Anaplastic Large-Cell Lymphoma: Current Understanding and Recommendations for Management.

Authors:  Tessa L St Cyr; Barbara A Pockaj; Donald W Northfelt; Fiona E Craig; Mark W Clemens; Raman C Mahabir
Journal:  Plast Surg (Oakv)       Date:  2020-05-21       Impact factor: 0.947

Review 2.  A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma.

Authors:  Houli Zhao; Yiyun Wang; Elaine Tan Su Yin; Kui Zhao; Yongxian Hu; He Huang
Journal:  Front Med       Date:  2020-12-01       Impact factor: 4.592

3.  Hematopoietic stem cell transplantation and chimeric antigen receptor T cell for relapsed or refractory diffuse large B-cell lymphoma.

Authors:  Tao Wang; Lei Gao; Yujie Wang; Wenjun Zhu; Lili Xu; Yang Wang; Wenqin Yue; Gusheng Tang; Li Chen; Jie Chen; Weiping Zhang; Xuejun Yu; Dongge Feng; Jianmin Yang
Journal:  Immunotherapy       Date:  2020-08-05       Impact factor: 4.196

Review 4.  Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.

Authors:  Andres Chang; Danielle Schlafer; Christopher R Flowers; Pamela B Allen
Journal:  Expert Opin Investig Drugs       Date:  2017-12-24       Impact factor: 6.206

Review 5.  The Role of PI3K Inhibition in Lymphoid Malignancies.

Authors:  Gottfried von Keudell; Alison J Moskowitz
Journal:  Curr Hematol Malig Rep       Date:  2019-10       Impact factor: 3.952

6.  MicroRNA-376a regulates cell proliferation and apoptosis by targeting forkhead box protein P2 in lymphoma.

Authors:  Shuna Yao; Yanyan Liu; Zhihua Yao; Yan Zhao; Haiying Wang; Yuanlin Xu; Jiuyang Zhang; Jing Li; Shujun Yang
Journal:  Oncol Lett       Date:  2018-06-22       Impact factor: 2.967

Review 7.  The role of interleukins and the widely studied TNF-α in non-Hodgkin's lymphoma.

Authors:  Kyle P D'mello; Lei Zhao; Erin C Kaser; Ziwen Zhu; Huaping Xiao; Mark R Wakefield; Qian Bai; Yujiang Fang
Journal:  Med Oncol       Date:  2021-04-09       Impact factor: 3.064

8.  Patients with Non-Hodgkin's Lymphoma Are at Risk of Adenomatous Colon Polyps.

Authors:  Hamzah Abu-Sbeih; Ellie Chen; Osman Ahmed; Niharika Mallepally; Phillip Lum; Wei Qiao; Hun Ju Lee; Robert Bresalier; Lan Sun Wang; Brian Weston; Gottumukkala S Raju; Yinghong Wang
Journal:  Dig Dis Sci       Date:  2019-05-03       Impact factor: 3.199

9.  SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model.

Authors:  Luca Ceriani; Giuseppe Gritti; Luciano Cascione; Maria Cristina Pirosa; Angela Polino; Teresa Ruberto; Anastasios Stathis; Andrea Bruno; Alden A Moccia; Luca Giovanella; Stefanie Hayoz; Sämi Schär; Stefan Dirnhofer; Alessandro Rambaldi; Giovanni Martinelli; Christoph Mamot; Emanuele Zucca
Journal:  Blood Adv       Date:  2020-03-24

Review 10.  Artemisinin-type drugs for the treatment of hematological malignancies.

Authors:  R I Mancuso; M A Foglio; S T Olalla Saad
Journal:  Cancer Chemother Pharmacol       Date:  2020-11-03       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.